Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)
| Conditions: | Mesothelioma, Lung Cancer |
| Start Date: | June 1, 2005 |
| Phase: | Phase III |
| Status: | Recruiting |
| NCT ID: | NCT00128102 |
| Study Type: | Interventional |
| Intervention: | Drug: vorinostat|Drug: Placebo |
| Study Design: | Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Merck |
| Ages: | Adult|Senior |
| Enrollment: | 660 |
| Funded By: | Industry |
| First Received: | August 5, 2005 |
| End Date: | January 1, 2013 |
| Last Updated: | October 22, 2010 |
| Last Verified: | October 1, 2010 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
